Full Text
Orphan Disease Drug Costs In The United States- Assessment Of Launch Pricing Trends In Non-Cancer Orphan Diseases And The Future Implications On Health System Access

Abstract

Authors

E.A. Davis E.L. Schwartz

Back to Volume 16, Issue 3
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×